Lead Product(s): Imatinib Mesylate
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Small molecule
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 08, 2020
Aerami will be responsible for the overall development and commercialisation of inhaled imatinib, with Vectura providing development services expertise and a license to its FOX® mesh nebuliser technology.